论文部分内容阅读
急性心肌梗死最有效的治疗策略是溶栓或经皮冠状动脉介入性治疗再通梗阻血管,但心肌缺血/再灌注(I/R)损伤限制了经皮冠状动脉介入性治疗和溶栓的益处,提示需要进一步的辅助治疗。近年来,肾素-血管紧张素系统在心肌I/R中的作用日受关注,在心肌I/R过程中循环系统和心肌局部血管紧张素Ⅱ(AngⅡ)含量增加,参与I/R损伤的发展。动物模型研究证实,AngⅡ1型受体(AT1受体)阻滞剂对心肌I/R损伤具有保护作用。临床试验验证AT1受体阻滞剂在冠状动脉粥样硬化性心脏病患者是安全、有效的。
The most effective treatment strategy for acute MI is thrombolysis or percutaneous coronary intervention to reopen obstruction of blood vessels, but myocardial ischemia / reperfusion (I / R) injury limits the need for percutaneous coronary intervention and thrombolysis Benefits, tips need further adjuvant therapy. In recent years, the role of the renin-angiotensin system in myocardial I / R has been paid more attention. The content of angiotensin Ⅱ (AngⅡ) in the circulatory system and myocardium during myocardial I / R is increased, which is involved in I / R injury development of. Animal model studies have confirmed that Ang Ⅱ 1 receptor (AT1 receptor) blockers have a protective effect on myocardial I / R injury. Clinical trials have demonstrated that AT1 receptor blockers are safe and effective in patients with coronary atherosclerotic heart disease.